Dr. John Matthew Ringman, MD

Dr. Ringman practices at Keck Hospital of USC in Los Angeles, California, part of University of Southern California.

Dr. Ringman's NPI, 1265451173, was assigned on July 19, 2006. Dr. Ringman graduated from McGill University Faculty of Medicine in 1993. Dr. Ringman holds California license G83793.

Dr. Ringman's primary practice is Keck Hospital of USC, at 1500 San Pablo Street, Los Angeles, CA 90033 in Los Angeles County. The practice phone is (323) 442-8656.

Dr. Ringman's primary practice is Keck Hospital of USC in Los Angeles, California, part of University of Southern California. Dr. Ringman is also affiliated with USC Verdugo Hills Hospital. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Ringman to 1 more group practice or clinic, 1 other site and 1 urgent care center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ringman practices, 5 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Ringman's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Ringman is board certified in neurology by the American Board of Psychiatry and Neurology. Dr. Ringman is licensed in California.

Dmand AI lists alzheimer's disease, encephalopathy and non-alzheimer's dementia (chronic) among the conditions Dr. Ringman treats.

CMS data shows 423 Medicare services from Dr. Ringman across 5 procedure codes in 2024, for 198 Medicare patients. Medicare paid $27,075 for them.

CMS counts 198 Medicare patients who saw Dr. Ringman in 2024. The largest group is 75 to 84, with 91 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 32% are also on Medicaid. Their average risk score is 1.46, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ringman's median patient age at 79, with 54% women.

In 2024, Dr. Ringman wrote 788 Medicare Part D claims for 117 patients. 98% of them were for generic drugs. CMS names the drug for 714 of them, across 9 drugs with 11 or more claims each, at $14,110 in total drug cost. In 2023, CMS named 707 claims across 10 drugs.

Dr. Ringman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ringman as offering telehealth.

Dmand AI links 48 papers to Dr. Ringman, published from 2012 to 2025. 2020 was the busiest year, with 8. The most frequent topics are Alzheimer Disease. Dr. Ringman has published most often in medRxiv. Dr. Ringman's most frequent co-authors are Eric Martin McDade, DO, James McCallum Noble, MD and Nigel Cairns, MD.

Dmand AI links Dr. Ringman to 6 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Alzheimer Disease, Tauopathies and Alzheimer disease, familial, type 3. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Ringman that name 1 trial.

CMS Open Payments shows 5 general payments to Dr. Ringman from 3 drug and device companies from 2017 to 2024. Consulting fees make up the largest share, 92% of the total. Eisai Inc. paid the most, $3,314. It also lists 1 research payment totaling $308 in 2016, naming 1 clinical trial.

Dr. Ringman graduated from McGill University Faculty of Medicine in 1993.

Dr. Ringman is in network with 9 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.